American Journal of Cardiovascular Drugs最新文献

{"title":"Comment on: “Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study”","authors":"Chia Siang Kow, Abdullah Faiz Zaihan, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan","doi":"10.1007/s40256-023-00626-0","DOIUrl":"10.1007/s40256-023-00626-0","url":null,"abstract":"","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"24 2","pages":"325 - 326"},"PeriodicalIF":2.8,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139545046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author’s Reply to Kow et al.: “Comparison of Clinical Outcomes between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study”","authors":"Hsiu-Yu Fang, Wei-Chieh Lee","doi":"10.1007/s40256-023-00627-z","DOIUrl":"10.1007/s40256-023-00627-z","url":null,"abstract":"","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"24 2","pages":"327 - 328"},"PeriodicalIF":2.8,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139545014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SAMe-TT2R2 Score to Predict Time in Therapeutic Range of Vitamin K Antagonists in Asian and Non-Asian patients: A Systematic Review and Meta-analysis","authors":"Natnicha Poonchuay,&nbsp;Surasak Saokaew,&nbsp;Supatcha Incomenoy","doi":"10.1007/s40256-023-00623-3","DOIUrl":"10.1007/s40256-023-00623-3","url":null,"abstract":"<div><h3>Background</h3><p>Sex, age, medical history, treatment, tobacco use, and race (SAMe-TT₂R₂) score helps detect patients at risk of suboptimal anticoagulation control. A score above two suggests poor control; however, non-Caucasian status being assigned two points might hinder the recognition of poor control in patients of other races.</p><h3>Objective</h3><p>To evaluate the SAMe-TT₂R₂ score’s ability to predict poor anticoagulation control [defined as time in therapeutic range (TTR) &lt; 60–70%] in Asian and non-Asian populations on vitamin K antagonists (VKAs).</p><h3>Methods</h3><p>We searched PubMed, Cochrane Library, Scopus, SpringerLink, and Web of Science using the keyword “SAMe-TT₂R₂.” Articles published before April 2022 were screened. We gathered mean TTR and diagnostic accuracy data for different SAMe-TT₂R₂ thresholds and conducted meta-analyses using random-effects models.</p><h3>Results</h3><p>A total of 30 studies were included (<i>N</i> = 36,690). The overall mean TTR differences were − 4.88 and − 6.41 for the cutoffs of ≥ 3 and ≥ 4, respectively. For non-Asian patients, the mean TTR differences were − 3.86, − 5.12, and − 8.09 for the cutoffs ≥ 2, ≥ 3, and ≥ 4, respectively. For Asian patients, the mean TTR differences were − 3.99 and − 4.07 for the cut-offs ≥ 3 and ≥ 4, respectively. The highest positive likelihood ratio (LR+) for the Asian subgroup was 1.17 [95% confidence interval (CI): 1.06–1.28; <i>I</i>² = 0%, <i>p</i> heterogeneity = 0.500] at cutoff ≥ 4 and for the non-Asian subgroup, at cut-off ≥ 3, the LR+ was 1.24 (95% CI 1.14–1.34; <i>I</i>² = 0% <i>p</i> heterogeneity = 0.455). The lowest LR− was found at a lower cutoff for both races (at cutoff ≥ 3 and ≥ 2 for Asian and non-Asian subgroups, respectively). The pooled results of other accuracy parameters were modest at all cutoffs, except for the sensitivity at cutoff ≥ 3 in the Asian subgroup (83.05%).</p><h3>Conclusion</h3><p>Our study results suggest that a higher SAMe-TT₂R₂ score resulted in a greater reduction of TTR among Asian and all races. The accuracy parameters showed the highest sensitivity for poor TTR at the SAMe-TT₂R₂ cutoff of ≥ 3 for Asian patients. However, the ability to identify patients likely to have poor TTR was limited. Further research is needed to enhance the risk assessment for poor anticoagulation control with VKAs.</p><h3>Registration</h3><p>The protocol of this systematic review was registered in the International Prospective Register of Scientific Reviews: PROSPERO, registration number CRD42021291865.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"24 2","pages":"211 - 240"},"PeriodicalIF":2.8,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139511616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials","authors":"Ahmed Atia,&nbsp;Heba Aboeldahab,&nbsp;Ahmed Wageeh,&nbsp;Mohamed Elneny,&nbsp;Mohamed Elmallahy,&nbsp;Bashaer Elawfi,&nbsp;Menna M. Aboelkhier,&nbsp;Amr Elrosasy,&nbsp;Maya Magdy Abdelwahab,&nbsp;Somaya Sayed,&nbsp;Ahmed Abdelaziz","doi":"10.1007/s40256-023-00621-5","DOIUrl":"10.1007/s40256-023-00621-5","url":null,"abstract":"<div><h3>Background</h3><p>Elevated circulating cholesterol levels in patients with acute coronary syndrome (ACS) increase morbidity and mortality. Recent studies reported that PCSK9 inhibitors (PCSK9i) have a beneficial effect on various domains of patients’ lipid profiles and cardiovascular and mortality outcomes. Here, we aim to further investigate the efficacy and safety of PCSK9i in patients with ACS or who experienced recent episodes.</p><h3>Methods</h3><p>We comprehensively searched PubMed, Scopus, Web of Science and Cochrane CENTRAL to identify all randomized controlled trials comparing PCSK9i versus placebo. Data were extracted and analysed using Stata/MP version 17.0.</p><h3>Results</h3><p>Eleven studies (<i>n</i> = 24,732) were included in this meta-analysis. In terms of efficacy outcomes, compared with the control group, PCSK9i significantly decreased levels of LDL-C, TC, TG, Lp (a) and Apo-B, with the following values, respectively: Cohen’s <i>d</i> of − 1.25, 95% confidence interval (CI − 1.64 to − 0.87); Cohen’s <i>d</i> of − 1.32, 95% CI (− 1.83 to − 0.81); Cohen’s <i>d</i> of − 0.26, 95% CI (− 0.37 to − 0.14); Cohen’s <i>d</i> of − 0.70, 95% CI (− 1.15 to − 0.26); and Cohen’s <i>d</i> of − 1.46, 95% CI (− 1.97 to − 0.94). The levels of HDL-C and Apo-A1 increased by: Cohen’s <i>d</i> 0.27, 95% CI (0.16–0.39) and Cohen’s <i>d</i> of 0.30, 95% CI (0.17–0.42), respectively. Regarding safety outcomes, PCSK9i was associated with lower odds of myocardial infarction (MI) and cerebrovascular events with the following values, respectively: OR = 0.87, 95% CI (0.78–0.97) and OR = 0.71, 95% CI (0.52–0.98).</p><h3>Conclusions</h3><p>PCSK9i was associated with better lipid profile and quality of life of patients and can be recommended as an optimal treatment strategy. Further trials should study combinations of PCSK9i with other lipid-lowering drugs.</p></div>","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"24 1","pages":"83 - 102"},"PeriodicalIF":2.8,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10806009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139490341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2 Inhibitors for Heart Failure with Preserved Ejection Fraction: What Hospitalists Need to Know","authors":"Stephen J. Greene,&nbsp;Gregg C. Fonarow,&nbsp;Javed Butler","doi":"10.1007/s40256-023-00624-2","DOIUrl":"10.1007/s40256-023-00624-2","url":null,"abstract":"","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"24 1","pages":"1 - 4"},"PeriodicalIF":2.8,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139064236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron Dyshomeostasis and Mitochondrial Function in the Failing Heart: A Review of the Literature","authors":"Seyed Ali Mousavi-Aghdas,&nbsp;Ebrahim Farashi,&nbsp;Nasim Naderi","doi":"10.1007/s40256-023-00619-z","DOIUrl":"10.1007/s40256-023-00619-z","url":null,"abstract":"<div><p>Cardiac contraction and relaxation require a substantial amount of energy provided by the mitochondria. The failing heart is adenosine triphosphate (ATP)- and creatine-depleted. Studies have found iron is involved in almost every aspect of mitochondrial function, and previous studies have shown myocardial iron deficiency in heart failure (HF). Many clinicians advocated intravenous iron repletion for HF patients meeting the conventional criteria for systemic iron deficiency. While clinical trials showed improved quality of life, iron repletion failed to significantly impact survival or significant cardiovascular adverse events. There is evidence that in HF, labile iron is trapped inside the mitochondria causing oxidative stress and lipid peroxidation. There is also compelling preclinical evidence demonstrating the detrimental effects of both iron overload and depletion on cardiomyocyte function. We reviewed the mechanisms governing myocardial and mitochondrial iron content. Mitochondrial dynamics (i.e., fusion, fission, mitophagy) and the role of iron were also investigated. Ferroptosis, as an important regulated cell death mechanism involved in cardiomyocyte loss, was reviewed along with agents used to manipulate it. The membrane stability and iron content of mitochondria can be altered by many agents. Some studies are showing promising improvement in the cardiomyocyte function after iron chelation by deferiprone; however, whether the in vitro and in vivo findings will be reflected on on clinical grounds is still unclear. Finally, we briefly reviewed the clinical trials on intravenous iron repletion. There is a need for more well-simulated animal studies to shed light on the safety and efficacy of chelation agents and pave the road for clinical studies.</p></div>","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"24 1","pages":"19 - 37"},"PeriodicalIF":2.8,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139064885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective","authors":"Andre Lamy,&nbsp;John Eikelboom,&nbsp;Wesley Tong,&nbsp;Fei Yuan,&nbsp;Shrikant I. Bangdiwala,&nbsp;Jackie Bosch,&nbsp;Stuart Connolly,&nbsp;Eva Lonn,&nbsp;Gilles R. Dagenais,&nbsp;Kelley R. H. Branch,&nbsp;Wei-Jhih Wang,&nbsp;Deepak L. Bhatt,&nbsp;Jeffrey Probstfield,&nbsp;Georg Ertl,&nbsp;Stefan Störk,&nbsp;P. Gabriel Steg,&nbsp;Victor Aboyans,&nbsp;Isabelle Durand-Zaleski,&nbsp;Lars Ryden,&nbsp;Salim Yusuf","doi":"10.1007/s40256-023-00620-6","DOIUrl":"10.1007/s40256-023-00620-6","url":null,"abstract":"<div><h3>Background</h3><p>Rivaroxaban 2.5 mg twice daily with aspirin 100 mg daily was shown to be better than aspirin 100 mg daily for preventing cardiovascular (CV) death, stroke or myocardial infarction in patients with either stable coronary artery disease (CAD) or peripheral artery disease (PAD). The cost-effectiveness of this regimen in this population is essential for decision-makers to know.</p><h3>Methods</h3><p>US direct healthcare system costs (in USD) were applied to hospitalized events, procedures and study drugs utilized by all patients. We determined the mean cost per participant for the full duration of the trial (mean follow-up of 23 months) plus quality-adjusted life years (QALYs) and the incremental cost-effectiveness ratio (ICER) over a lifetime using a two-state Markov model with 1-year cycle length. Sensitivity analyses were performed on the price of rivaroxaban and the annual discontinuation rate.</p><h3>Results</h3><p>The costs of events and procedures were reduced for Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) patients who received rivaroxaban 2.5 mg orally (BID) plus acetylsalicylic acid (ASA) compared with ASA alone. Total costs were higher for the combination group ($7426 versus $4173) after considering acquisition costs of the study drug. Over a lifetime, patients receiving rivaroxaban plus ASA incurred $27,255 more and gained 1.17 QALYs compared with those receiving ASA alone resulting in an ICER of $23,295/QALY. ICERs for PAD only and polyvascular disease subgroups were lower.</p><h3>Conclusion</h3><p>Rivaroxaban 2.5 mg BID plus ASA compared with ASA alone was cost-effective (high value) in the USA.</p><p><b>COMPASS ClinicalTrials.gov identifier</b>: NCT01776424.</p></div>","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"24 1","pages":"117 - 127"},"PeriodicalIF":2.8,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10806169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139048175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rivaroxaban Plasma Concentration and Clinical Outcomes on Older Patients with Non-valvular Atrial Fibrillation and Pulmonary Infection","authors":"Yan Yu,&nbsp;Haobin Li,&nbsp;Jing Liu,&nbsp;Qing Liang,&nbsp;Juan Xie,&nbsp;Guangchun Sun","doi":"10.1007/s40256-023-00622-4","DOIUrl":"10.1007/s40256-023-00622-4","url":null,"abstract":"<div><h3>Introduction</h3><p>Infection may induce thrombotic and hemorrhagic events; however, it is currently unclear whether the inflammatory response affects the coagulation function and the clinical efficacy and safety of rivaroxaban in older patients with non-valvular atrial fibrillation (NVAF).</p><h3>Objective</h3><p>This project aimed to assess the effectiveness and safety of the non-vitamin K antagonist oral anticoagulant rivaroxaban in older patients with NVAF complicated by infection, and to provide a basis for possible drug dose adjustment.</p><h3>Methods</h3><p>A total of 152 NVAF patients aged ≥ 65 years admitted to the Fifth People’s Hospital of Shanghai from June 2020 to May 2022 were included in this prospective, observational study. The changes in steady-state plasma concentration of rivaroxaban and FXa inhibition rate were compared between patients with and without infection, and the impact on the occurrence of infection, thrombotic events, and bleeding events was compared through 1-year follow-up.</p><h3>Results</h3><p>Our results showed that patients in the infection group had abnormal inflammation markers, as well as an increased occurrence of bleeding and thrombotic events during hospitalization and follow-up. The high incidence of bleeding events in patients was closely related to the occurrence of infection, lymphocyte reduction, and increased neutrophil-lymphocyte ratio. The increase in thrombotic events was related to a decrease in rivaroxaban plasma concentration. Bleeding events in patients taking anticoagulant drugs are not necessarily due to drug accumulation.</p><h3>Conclusions</h3><p>Timely control of infection, assessment of bleeding and thrombotic risks, and selection of appropriate anticoagulation treatment strategies should be made in older NVAF patients who develop pulmonary infection.</p><h3>Clinical Trials Registration</h3><p>Chinese Clinical Trial Registry Number ChiCTR2000033144.</p></div>","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"24 1","pages":"129 - 139"},"PeriodicalIF":2.8,"publicationDate":"2023-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139032031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis","authors":"Mostafa Reda Mostafa,&nbsp;Mohamed Magdi Eid,&nbsp;Ahmed K. Awad,&nbsp;Andrew Takla,&nbsp;Abdul Rhman Hassan,&nbsp;Basant E. Katamesh,&nbsp;Majd M. AlBarakat,&nbsp;Abdul Rhman Ziada,&nbsp;Sarah Mohamed,&nbsp;Karim M. Al-Azizi,&nbsp;Andrew M. Goldsweig","doi":"10.1007/s40256-023-00616-2","DOIUrl":"10.1007/s40256-023-00616-2","url":null,"abstract":"<div><h3>Introduction</h3><p>Cangrelor is a potent intravenous non-thienopyridine P2Y12 inhibitor. We conducted a network meta-analysis to study the efficacy and safety of cangrelor as compared with the oral P2Y12 inhibition, clopidogrel, or placebo in acute coronary syndromes.</p><h3>Methods</h3><p>This meta-analysis followed the Cochrane collaboration guidelines and the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) protocols. Outcomes of interest included all-cause mortality, myocardial infarction, stent thrombosis, target vessel revascularization, major bleeding, minor bleeding, and the need for blood transfusion.</p><h3>Results</h3><p>The analysis was comprised of 6 studies including 26,444 patients treated with cangrelor, clopidogrel, or placebo. There were no statistically significant differences in the incidence of all-cause mortality, myocardial infarction, stent thrombosis, target vessel revascularization, or major bleeding. Cangrelor was associated with a higher risk of minor bleeding than clopidogrel or placebo, with no difference in requiring blood transfusion.</p><h3>Conclusion</h3><p>Cangrelor has comparable outcomes to clopidogrel in patients with acute coronary syndromes and can be used as a reliable alternative in this population.</p></div>","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"24 1","pages":"71 - 81"},"PeriodicalIF":2.8,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138294438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review","authors":"Ryaan EL-Andari,&nbsp;Nicholas M. Fialka,&nbsp;Jimmy Kang,&nbsp;Sabin J. Bozso,&nbsp;Jayan Nagendran,&nbsp;Jeevan Nagendran","doi":"10.1007/s40256-023-00618-0","DOIUrl":"10.1007/s40256-023-00618-0","url":null,"abstract":"<div><h3>Introduction</h3><p>Diabetes and coronary artery disease are two common conditions that often co-exist. In recent years, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been demonstrated to provide significant cardioprotective benefits, especially among patients with heart failure.</p><h3>Objective</h3><p>In this systematic review, we look to identify the outcomes SGLT2i use in patients undergoing coronary revascularization.</p><h3>Methods</h3><p>Pubmed and Embase were systematically searched for articles describing the outcomes of patients taking SGLT2i and undergoing coronary revascularization. 834 titles and abstracts were screened, 42 full texts were reviewed, and 18 studies were found to meet the inclusion criteria and were included in this review.</p><h3>Results</h3><p>For patients undergoing coronary artery bypass grafting and percutaneous coronary intervention, the use of SGLT2i resulted in reductions in mortality, hospitalization for heart failure, and improved blood glucose; however, these benefits were not consistently reported in the literature. Reduced inflammatory markers and positive cardiac remodeling were identified among patients taking SGLT2i.</p><h3>Conclusions</h3><p>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been demonstrated to provide benefits for patients with heart failure along with a host of positive modulatory effects on the cardiovascular system, including reductions in inflammatory properties, hypertension, and left ventricular volume load. Given the clear benefit provided by SGLT2i to patients with cardiovascular disease and a host of positive properties that are expected to be protective for patients with ischemic heart disease, future investigation into the relationship between SGLT2i and outcomes for patients undergoing revascularization is imperative.</p></div>","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"24 1","pages":"55 - 69"},"PeriodicalIF":2.8,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136395876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}